Your search for Naltrexone returned 9 results. Search again.
Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.
NIDA grantee Dr. O’Brien was honored for his “exemplary personal commitment to French‒American relations as symbolized by … exceptional cooperation in science and in public health.”
More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
NIDA researcher Dr. Charles O’Brien recently received the James B. Isaacson Award for a lifetime of research on the biological basis of alcoholism.
Reports findings from a survey that revealed that although substance abuse is prevalent in jails and prisons, many correctional facilities do not offer detoxification services or therapies to aid in maintaining abstinence.
Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.
Reports on a study investigating the effectiveness of a combined therapy of disulfiram and naltrexone for people who abuse cocaine and alcohol.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.